Synaptotagmin XIII, KIAA1427, synaptotagmin-13, sytXIII.
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Synaptotagmin XIII, KIAA1427, synaptotagmin-13, sytXIII.
Synaptotagmin XIII (SYT13) is a member of the synaptotagmin family, which consists of membrane-trafficking proteins characterized by an N-terminal transmembrane region, a variable linker, and two C-terminal C2 domains (C2A and C2B) . Synaptotagmins play crucial roles in the regulation of neurotransmitter release and hormone secretion.
Synaptotagmin XIII, like other synaptotagmins, has a transmembrane region that anchors it to the membrane, and two C2 domains that are involved in calcium binding and interactions with other proteins . The C2 domains are essential for the protein’s role in exocytosis, where it acts as a calcium sensor to trigger the fusion of synaptic vesicles with the presynaptic membrane .
The human recombinant form of Synaptotagmin XIII is produced in E. coli and is a single, non-glycosylated polypeptide chain containing 420 amino acids (30-426) with a molecular mass of 46.5 kDa . This recombinant protein is often used in research to study its function and interactions in a controlled environment.
Synaptotagmin XIII is involved in the regulation of neurotransmitter release. It acts as a calcium sensor, and upon binding calcium, it triggers the fusion of synaptic vesicles with the presynaptic membrane, leading to the release of neurotransmitters into the synaptic cleft . This process is crucial for the proper functioning of synaptic transmission and communication between neurons.
The recombinant form of Synaptotagmin XIII is used in various research applications to study its biochemical properties, interactions with other proteins, and its role in neurotransmission. Understanding the function of Synaptotagmin XIII can provide insights into the mechanisms of synaptic transmission and potential therapeutic targets for neurological disorders.